The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

unistra.fr

Founded Year

2009

About University of Strasbourg

DescriptionThe University of Strasbourg in Strasbourg, Alsace, France, is a university in France.

University of Strasbourg Headquarter Location

4 Rue Blaise Pascal

Strasbourg, 67081,

France

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

University of Strasbourg Patents

University of Strasbourg has filed 2 patents.

The 3 most popular patent topics include:

  • Colloidal chemistry
  • Condiments
  • Fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/22/2010

11/17/2020

Colloidal chemistry, Fluid dynamics, Microfluidics, Biotechnology, Chemical mixtures

Grant

Application Date

12/22/2010

Grant Date

11/17/2020

Title

Related Topics

Colloidal chemistry, Fluid dynamics, Microfluidics, Biotechnology, Chemical mixtures

Status

Grant

Latest University of Strasbourg News

Captor Therapeutics to Host R&D Day on May 18, 2022

May 5, 2022

May 05, 2022 03:00 ET Wroclaw, POLAND WROCŁAW, Poland, May 05, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces it will host a virtual Research and Development (R&D) day on Wednesday 18 May 2022 at 10:00 am EDT (04:00 pm CEST). Captor's executive management team will discuss the company's broadly applicable OptigradeTM platform and how it allows for the sustainable creation and discovery of TPD drugs. Chief Scientific Officer Michał Walczak, PhD, and Biology Department Director Paweł Dobrzański, PhD, will describe Captor's CT-01 program in hepatocellular carcinoma (HCC) and its potential to redefine the HCC treatment paradigm. The event will also feature a presentation by Key Opinion Leader Thomas F. Baumert, MD from the University of Strasbourg on the unmet medical need in HCC and the current landscape of HCC drugs and patient treatments. To register for the webinar, please click here . A live question and answer session will also be held. If you would like to ask a question during the session, please submit your request to questions@lifesciadvisors.com . For those who are unable to attend, a replay of the webinar will be available here . About Thomas F. Baumert, MD Thomas F. Baumert, MD is Professor of Medicine, head of the Inserm Research Institute for Viral and Liver Diseases (Inserm U1110), director of the Laboratory of Excellence HEPSYS at the University of Strasbourg and Chair of Hepatology at the Center for Digestive Disease and Hepatology at the Strasbourg University Hospitals. His research focuses on the modelling and discovery of the cell circuits underlying liver disease progressing to cancer. The understanding of the molecular mechanisms of liver disease biology enabled his laboratory to uncover novel strategies for the treatment of chronic liver disease and hepatocellular carcinoma. He has received many awards, including five European Research Council (ERC) awards for the discovery and development of novel approaches to prevent and treat chronic liver disease. He has published more than 400 scientific articles in prestigious peer-reviewed journals, such as Cell, Nature, Nature Medicine, Nature Biotechnology, Cell Host & Microbe, PNAS as a senior author and is an inventor on 16 patents and patent applications. Dr. Baumert is Associate Editor of the Journal of Hepatology and serves as a member of the editorial board of several journals in the fields of Gastroenterology, Hepatology, Virology and Infectious Diseases. He is a member of the US, European, French, and German Liver Societies and an elected member of the American Association of Physicians (AAP). Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer. About Captor Therapeutics Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases. More information on Captor Therapeutics is available at:  http://www.captortherapeutics.com

University of Strasbourg Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

University of Strasbourg Rank

  • When was University of Strasbourg founded?

    University of Strasbourg was founded in 2009.

  • Where is University of Strasbourg's headquarters?

    University of Strasbourg's headquarters is located at 4 Rue Blaise Pascal, Strasbourg.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.